Edwards Lifesciences Corp
EW80.500USD
0.0000.00%
交易中 （美东）报价延迟15分钟
46.75B总市值
34.28市盈率 TTM
关于 Edwards Lifesciences Corp 公司
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Edwards Lifesciences Corp简介
公司代码EW
公司名称Edwards Lifesciences Corp
上市日期Mar 27, 2000
CEOZovighian (Bernard J)
员工数量15800
证券类型Ordinary Share
年结日Mar 27
公司地址One Edwards Way
城市IRVINE
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编92614
电话19492502500
网址https://www.edwards.com
公司代码EW
上市日期Mar 27, 2000
CEOZovighian (Bernard J)
Edwards Lifesciences Corp公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
282.82K
--
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
76.00K
+4682.00%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
39.57K
--
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
21.26K
--
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
17.91K
-2000.00%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.84K
+3528.00%
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
业务USD
名称
营收
占比
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
地区USD
名称
营收
占比
United States
907.50M
58.43%
Europe
387.90M
24.98%
Rest of the world
167.60M
10.79%
Japan
90.10M
5.80%
业务
地区
业务USD
名称
营收
占比
Transcatheter Aortic Valve Replacement
1.15B
74.04%
Surgical Heart Valve Therapy
258.00M
16.61%
Transcatheter Mitral and Tricuspid Therapies
145.20M
9.35%
股东统计
更新时间: 1月10日 周六
更新时间: 1月10日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
其他
71.62%
持股股东
持股股东
占比
The Vanguard Group, Inc.
12.03%
BlackRock Institutional Trust Company, N.A.
5.26%
State Street Investment Management (US)
4.41%
Wellington Management Company, LLP
3.59%
JP Morgan Asset Management
3.09%
其他
71.62%
股东类型
持股股东
占比
Investment Advisor
46.83%
Investment Advisor/Hedge Fund
30.96%
Hedge Fund
3.47%
Pension Fund
2.27%
Research Firm
2.17%
Bank and Trust
1.96%
Sovereign Wealth Fund
1.37%
Individual Investor
0.93%
Endowment Fund
0.83%
其他
9.21%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
2452
517.66M
93.53%
--
2025Q3
2537
517.80M
94.00%
-1.50M
2025Q2
2614
519.17M
94.35%
-5.19M
2025Q1
2599
525.51M
93.66%
-25.15M
2024Q4
2585
522.16M
89.45%
+17.15M
2024Q3
2546
504.88M
87.53%
-10.03M
2024Q2
2541
515.71M
87.77%
+1.93M
2024Q1
2555
513.21M
86.74%
-8.92M
2023Q4
2556
503.19M
87.55%
-12.35M
2023Q3
2509
516.79M
88.03%
-521.37K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
70.09M
12.08%
+359.01K
+0.51%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
30.52M
5.26%
-370.16K
-1.20%
Sep 30, 2025
State Street Investment Management (US)
25.62M
4.41%
-14.75K
-0.06%
Sep 30, 2025
Wellington Management Company, LLP
20.80M
3.59%
+977.93K
+4.93%
Sep 30, 2025
JP Morgan Asset Management
17.92M
3.09%
-2.17M
-10.80%
Sep 30, 2025
Jennison Associates LLC
13.96M
2.41%
+2.29M
+19.60%
Sep 30, 2025
Fidelity Management & Research Company LLC
13.03M
2.25%
+10.73M
+466.56%
Sep 30, 2025
Geode Capital Management, L.L.C.
12.84M
2.21%
+114.73K
+0.90%
Sep 30, 2025
Walter Scott & Partners Ltd.
9.96M
1.72%
+1.05M
+11.73%
Sep 30, 2025
Union Investment Privatfonds GmbH
8.60M
1.48%
+19.17K
+0.22%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares U.S. Medical Devices ETF
4.72%
Future Fund Long/Short ETF
3.86%
iShares Health Innovation Active ETF
3.65%
Global X Aging Population ETF
3.31%
Acruence Active Hedge US Equity ETF
2.58%
First Trust Indxx Medical Devices ETF
2.23%
State Street SPDR S&P Health Care Equipment ETF
1.88%
JPMorgan Healthcare Leaders ETF
1.8%
PGIM Jennison Better Future ETF
1.78%
ROBO Global Healthcare Technology & Innovation ETF
1.73%
查看更多
iShares U.S. Medical Devices ETF
占比4.72%
Future Fund Long/Short ETF
占比3.86%
iShares Health Innovation Active ETF
占比3.65%
Global X Aging Population ETF
占比3.31%
Acruence Active Hedge US Equity ETF
占比2.58%
First Trust Indxx Medical Devices ETF
占比2.23%
State Street SPDR S&P Health Care Equipment ETF
占比1.88%
JPMorgan Healthcare Leaders ETF
占比1.8%
PGIM Jennison Better Future ETF
占比1.78%
ROBO Global Healthcare Technology & Innovation ETF
占比1.73%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
May 07, 2020
Split
1→3
公告日期
除权除息日
类型
比率
May 07, 2020
Split
1→3
